Skip to main content

Advertisement

Table 2 Sociodemographic, economic, and clinical characteristics of patients upon admission to the study

From: Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and immune response of HIV patients on antiretroviral therapy: a single-blind randomized control trial

Variables Moringa group Median (min–max) Control group Median (min–max) P
Gender
Male   24   23 0.99
Female   76   77  
Age (years) 49.5 (21–64)   47.0 (18–61)   0.45
18–49   50   70 0.78
50–64   50   30  
Marital status
Married   33   30 0.11
Others   67   70  
Living Environment
At home   47   67 0.12
With third party   53   33  
Household size
No children   10   13 0.91
≤3 children   43   43  
≥4 children   47   43  
Educational level
Low   60   80 0.09
High   40   20  
Professional activity
Not engaged   37   43 0.59
Engaged   63   57  
Anthropometric parameters
Height (cm) 164.0 (6.0)   163.1 (7.9)   0.55
Weight (kg) 59.6 (12.9)   56.9 (10.8)   0.29
BMI (kg/m2) 21.8 4.2)   21.4 (3.8)   0.99
<18.5   23   20 0.75
≥18.5   77   80  
WHO Clinical staging
Stage 2   17   27 0.34
Stage 3 & 4   83   73  
Duration of ART (years) 4.5 (1–8)   5.5 (0–14)   0.49
<5   70   50 0.11
≥5   30   50  
ART regimen*
AZT + 3TC + NVP   80   63 0.32
TDF + 3TC+ LPV/r   17   33  
ABC + DDI + LPV/r   3   3  
  1. ART antiretroviral therapy, AZT Zidovudine, 3TC Lamivudine; NVP, Nevirapine, TDF, Tenofovir; LPV/r Lopinavir +Ritonavir, ABC Abacavir, DDI, Didanosine